ESMO 2017: Adjuvant sunitinib in patients with high risk renal cell carcinoma (RCC): Safety and therapy management in S-TRAC trial

Madrid, Spain (UroToday.com) Dr. Michael Staehler and colleagues presented a post-hoc analysis of the S-TRAC trial assessing adjuvant sunitinib in patients with high risk renal cell carcinoma (RCC). As the author’s note, patients in S-TRAC with locoregional RCC at high risk (≥T3 and/or N+) of tumor recurrence post nephrectomy treated with adjuvant sunitinib (50 mg daily; schedule 4/2) had significantly longer disease-free survival (DFS) vs. placebo (HR 0.76; 95%CI, 0.59–0.98; p = 0.03) [1]. The objective of this analysis was to report safety and therapy management outcomes from this trial.

ESMO 2017: A Change of Paradigm in First-Line Treatment of Metastatic Renal Cell Carcinoma?

Madrid, Spain (UroToday.com) Dr. Manuela Schmidinger provided an excellent discussant commentary for the late-breaking abstract “CheckMate 214: Efficacy and safety of Nivolumab + Ipilimumab vs Sunitinib for treatment-naïve advanced or metastatic renal cell carcinoma (mRCC), including IMDC risk and PD-L1 expression subgroups” [1] presented by Dr. Escudier and colleagues. As. Dr. Schmidinger notes, for more than a decade now, VEGF-inhibitors have been first-line agents for patients with favorable or intermediate risk clear cell mRCC.

ESMO 2017: IMmotion150: Novel Radiological Endpoints and Updated Data From a Randomized Phase II Trial Investigating Atezolizumab With or Without Bevacizumab vs Sunitinib in Untreated Metastatic Renal Cell Carcinoma

Madrid, Spain (UroToday.com)Dr. Powles and colleagues presented updated results from the IMmotion150 trial assessing atezolizumab +/- bevacizumab vs sunitinib for untreated metastatic renal cell carcinoma (mRCC).

ESMO 2017: Progression-free survival by independent review and updated overall survival results from Alliance A031203 trial (CABOSUN): cabozantinib versus sunitinib as initial targeted therapy for patients with metastatic renal cell carcinoma

Madrid, Spain (UroToday.com) Dr. Choueiri and colleagues presented updated results from the CABOSUN trial, which randomized cabozantinib versus sunitinib as initial targeted therapy for patients with metastatic renal cell carcinoma (mRCC). Cabozantinib, an oral, potent inhibitor of MET, AXL, and VEGFR2, improved investigator-assessed PFS (primary endpoint) compared with sunitinib as initial targeted therapy in patients with mRCC of poor or intermediate risk [1].

ESMO 2017: Phase Ib/II Trial of Interleukin-2 and Nivolumab in Metastatic Clear Cell Renal Cell Cancer

Madrid, Spain (UroToday.com) At today’s ESMO 2017 poster session, Dr. Yentz and colleagues at the University of Michigan presented their trial design for assessing Interleukin-2 (IL-2) and nivolumab for patients with metastatic clear cell renal cell carcinoma (RCC). Despite the many systemic therapy advances for patients with metastatic RCC, high dose IL-2 immunotherapy remains a standard therapy for suitable patients with metastatic clear cell RCC who have good performance status.

ESMO 2017: CheckMate 214: Efficacy and safety of Nivolumab + Ipilimumab vs Sunitinib for treatment-naïve advanced or metastatic renal cell carcinoma, including IMDC risk and PD-L1 expression subgroups

Madrid, Spain (UroToday.com) Professor Escudier and colleagues presented results of their phase III CheckMate 214 trial assessing nivolumab + ipilimumab vs sunitinib for treatment-naïve advanced or metastatic renal cell carcinoma (mRCC). Nivolumab plus the CTLA-4 inhibitor ipilimumab combination previously demonstrated safety and high antitumor activity in previously treated and treatment-naïve patients with mRCC in the phase Ib CheckMate 016 study [1].

ESMO 2017: KEYNOTE-564: Phase 3 trial of pembrolizumab in the adjuvant treatment of renal cell carcinoma

Madrid, Spain (UroToday.com) Dr. Choueiri and colleagues presented their phase III trial design of adjuvant pembrolizumab for patients with renal cell carcinoma (RCC). Effective adjuvant therapies for patients with RCC at risk of recurrence after nephrectomy are lacking, and previous adjuvant therapy trials utilizing TKIs have proven disappointing [1-3].
Page 2 of 3
E-Newsletters

Newsletter subscription

Free Daily and Weekly newsletters offered by content of interest

The fields of GU Oncology and Urology are rapidly advancing. Sign up today for articles, videos, conference highlights and abstracts from peer-review publications by disease and condition delivered to your inbox and read on the go.

Subscribe